Ronald J. Buckanovich, MD, PhD, of the University of Michigan, discusses study findings on chemotherapy and cediranib in relapsed ovarian cancer. (Abstract 5506)
Arnaud Scherpereel, MD, PhD, of the University Hospital of Lille, discusses phase II study findings on second- or third-line nivolumab vs nivolumab plus ipilimumab in malignant pleural mesothelioma patients. (Abstract LBA8507)
Ethan M. Basch, MD, of the University of North Carolina, discusses results from a study that assessed patient-reported outcomes for symptom monitoring during routine cancer treatment of metastatic solid tumors. (Abstract LBA2)
Rakesh Chopra, MD, of India’s Artemis Hospitals, discusses ASCO’s Role in global cancer care and the issues he finds most pressing.
Lee S. Schwartzberg, MD, of West Cancer Center, reports on this past year’s progress of the ACCC initiative to speed adoption of immunotherapeutics in community practices.
Nicholas D. James, MBBS, PhD, of Queen Elizabeth Hospital, discusses study findings on adding abiraterone for men with high-risk prostate cancer starting long-term androgen-deprivation therapy (Abstract LBA5003).
